Despite the natural ability of the immune system to recognize cancer and, in some patients, even to eliminate it, cancer cells have acquired numerous evading mechanisms. With the increasing knowledge and focus shifting from targeting rapidly proliferating cells with chemotherapy to modulating the immune system, there have been recent efforts to integrate (e.g., simultaneously or sequentially) various therapeutic approaches. Combining the oncolytic activity of some chemotherapeutics with immunostimulatory molecules, so-called chemoimmunotherapy, is an attractive strategy. An example of such an immunostimulatory molecule is polyinosinic:polycytidylic acid [Poly(I:C)], a synthetic analogue of double-stranded RNA characterized by rapid nuclease degradation hampering its biological activity. This study investigated the possible interactions of tetracycline and anthracycline chemotherapeutics with different commercial Poly(I:C) molecules and protection against nuclease degradation. Fluorescence spectroscopy and circular dichroism revealed an interaction of all of the selected chemotherapeutics with Poly(I:C)s and the ability of doxycycline and minocycline to prolong the resistance to RNase cleavage, respectively. The partial protection was observed in vitro as well.
Interaction of Selected Anthracycline and Tetracycline Chemotherapeutics with Poly(I:C) Molecules.
阅读:4
作者:SkaliÄková Markéta, Abramenko Nikita, Charnavets Tatsiana, Vellieux Frédéric, Leischner Fialová JindÅiÅ¡ka, KuÄnirová KateÅina, KejÃk ZdenÄk, MasaÅÃk Michal, Martásek Pavel, Pacak Karel, Pacák Tomáš, Jakubek Milan
| 期刊: | ACS Omega | 影响因子: | 4.300 |
| 时间: | 2025 | 起止号: | 2025 Apr 15; 10(16):15935-15946 |
| doi: | 10.1021/acsomega.4c05483 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
